Credit Suisse Downgrades Sucampo Pharmaceuticals To Underperform

Analysts at Credit Suisse downgraded

from Neutral to Underperform. The price target for Sucampo Pharmaceuticals has been raised from $10.00 to $13.00. Sucampo Pharmaceuticals shares have gained 81.15% over the past 52 weeks, while the S&P 500 index has surged 14.02% in the same period. Sucampo Pharmaceuticals' shares fell 3.87% to close at $15.38 on Friday.